NEW YORK/WALTHAM - Dianthus Therapeutics, Inc. (NASDAQ:DNTH), currently valued at $1.17 billion, has priced its upsized public offering of 6,487,879 shares of common stock at $33.00 per share, the clinical-stage biotechnology company announced Tuesday. The stock has shown remarkable momentum, gaining over 46% in the past week alone, according to InvestingPro data.
The offering also includes pre-funded warrants to purchase up to 1,112,121 shares at $32.999 per warrant for certain investors. These warrants have an exercise price of $0.001 per share and are immediately exercisable.
The company expects to raise approximately $251 million in gross proceeds before deducting underwriting discounts, commissions and other offering expenses. Dianthus has also granted underwriters a 30-day option to purchase up to an additional 1,140,000 shares at the public offering price.
The offering is expected to close on September 11, 2025, subject to customary closing conditions.
Dianthus plans to use the proceeds to advance its preclinical and clinical development activities focused on antibody complement therapeutics for severe autoimmune diseases, as well as for working capital and general corporate purposes.
Jefferies, TD Cowen, Evercore ISI and Stifel are serving as joint book-running managers for the offering, with LifeSci Capital acting as lead manager.
The biotechnology company, based in New York and Waltham, Massachusetts, focuses on developing monoclonal antibodies with improved selectivity and potency for people living with severe autoimmune and inflammatory diseases.
This article is based on a press release statement from Dianthus Therapeutics.
In other recent news, Dianthus Therapeutics reported positive Phase 2 trial results for its experimental drug claseprubart in treating generalized Myasthenia Gravis (gMG). The trial involved 65 patients and showed statistically significant improvements in key efficacy measures, such as Myasthenia Gravis Activities of Daily Living and Quantitative Myasthenia Gravis scores. Following these results, Dianthus Therapeutics launched a $150 million public stock offering, with an option for underwriters to purchase an additional $22.5 million in shares. Analyst firms responded to the trial data by adjusting their price targets; Raymond James increased its target to $63 while maintaining an Outperform rating, and Guggenheim raised its target to $100, reiterating a Buy rating. H.C. Wainwright also reiterated its Buy rating with a $40 price target. These developments reflect heightened interest and optimism from analysts regarding Dianthus Therapeutics' potential in the biotech sector. The trial results have sparked discussions, particularly around ANA/ds-DNA seroconversion observed in some cases, though none were linked to Lupus-like clinical symptoms.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.